New FMO3 paper : A physiological role for flavin-containing monooxygenase (FMO3) in humans?

Flavin mono oxygenase 3 enzyme seems to be very much the ignored xenobiotic enzyme in medical research, despite dealing with probably thousands of substrates in humans, usually oxidizing soft-nucleophilic heteroatom compounds containing sulfur, nitrogen, or phosphorous to non-toxic excretable oxides. There seem to be few researchers interested, and fewer research papers. Someday the pharmaceutical industry will realize it may be a factor in drug metabolism, as can likely be taken for granted by the amount of TMAU people who anticipate bad reactions to drugs. Currently the only 'downside' of having poor FMO3 function is regarded as trimethylaminuira, so it is likely that without our own actions, it will not be until the pharmaceutical industry realizes the 'drug metabolism' factor that frequent serious research will be done into this enzyme.

One of the 'pioneers' in FMO3 research has been Dr Stephen Mitchell of London, who did most of his FMO3 papers in the late 80's and 90's. He also seemed to have a role in organizing the 1st TMAU workshop in 1999.

He has not published an FMO3 paper for most of the last decade, but recently published a new FMO3 paper along with RL Smith, who also has a history in FMO3 research (again, not recently).

The paper is entitled :
A physiological role for flavin-containing monooxygenase (FMO3) in humans?
http://www.ncbi.nlm.nih.gov/pubmed/20230247

Unfortunately for us there is not even an abstract available to the public, so we cannot get a summary of what the paper is about. If anyone has access, it would be interesting to know more.